The effects of probiotic Lactobacillus acidophilus and colchicine on the control of symptoms, duration, and disease progression of mild and moderate cases of COVID-19: A randomized controlled clinical trial

{ 'institution': [{'name': 'Research Square'}], 'indexed': {'date-parts': [[2023, 6, 14]], 'date-time': '2023-06-14T04:22:00Z', 'timestamp': 1686716520236}, 'posted': {'date-parts': [[2023, 6, 13]]}, 'group-title': 'In Review', 'reference-count': 32, 'publisher': 'Research Square Platform LLC', 'license': [ { 'start': { 'date-parts': [[2023, 6, 13]], 'date-time': '2023-06-13T00:00:00Z', 'timestamp': 1686614400000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2023, 6, 11]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>Background\n' ' Coronavirus disease 2019 (COVID-19) is a newly emerging human disease caused by a novel ' 'coronavirus, causing a global pandemic crisis. Probiotics and/or colchicine may be considered ' 'as options for treatment since they have anti-viral, anti-inflammatory, and immunomodulatory ' 'effects.\n' 'Objective\n' ' To assess the effectiveness of probiotic supplements (Lactobacillus acidophilus) and ' 'colchicine on symptoms, duration, and progression of mild and moderate cases of COVID-19 ' 'infection.\n' 'Methods\n' ' A three-arm randomized controlled clinical trial was carried out in the triage clinic of ' 'the family medicine department at Ain Shams University Hospitals on 150 participants who had ' 'been diagnosed as COVID-19 patients with mild and moderate severity. Patients aged below 18 ' 'years or above 65 years with any co-morbidities, pregnant or lactating females, and severe ' 'COVID-19 confirmed cases were excluded. Randomization was done by using sealed envelopes ' 'containing codes for intervention or control. Patients are followed up for improvement of ' 'their symptoms with no development of new symptoms over the course of two weeks.\n' 'Results\n' ' A total of 150 patients with mild and moderate severity of COVID-19 were enrolled in the ' 'study, 50 patients in each arm; around one third (34.7%) of the participants were aged ' 'between 29 and 39 years; one-quarter (24.7%) were aged between 18 and 28 years and 40.6% were ' 'aged 40 years and above. The mean duration of symptoms improvement was 12, 11 and 12 in the ' 'colchicine, probiotic, and control groups, respectively. Improvement of inflammatory markers ' 'over time occurred in each of the three groups, with no statistically significant difference ' 'between them.\n' 'Conclusion\n' ' Probiotic Lactobacillus acidophilus and colchicine shows no significant effect on the ' 'symptoms, duration, and progression of mild and moderate cases of COVID-19.</jats:p>', 'DOI': '10.21203/rs.3.rs-3049708/v1', 'type': 'posted-content', 'created': {'date-parts': [[2023, 6, 13]], 'date-time': '2023-06-13T20:48:50Z', 'timestamp': 1686689330000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The effects of probiotic Lactobacillus acidophilus and colchicine on the control of symptoms, ' 'duration, and disease progression of mild and moderate cases of COVID-19: A randomized ' 'controlled clinical trial', 'prefix': '10.21203', 'author': [ { 'given': 'Samar Osama Ahmed', 'family': 'Hassan', 'sequence': 'first', 'affiliation': [{'name': 'Ain Shams University Hospital'}]}, { 'given': 'Ahmed Nour El-Din', 'family': 'Hassan', 'sequence': 'additional', 'affiliation': [{'name': 'Ain Shams University Hospital'}]}, { 'given': 'Manal Sabry', 'family': 'Mohamed', 'sequence': 'additional', 'affiliation': [{'name': 'Ain Shams University Hospital'}]}, { 'given': 'Mohamed Nabil Badawy Al', 'family': 'Ashram', 'sequence': 'additional', 'affiliation': [{'name': 'Ain Shams University Hospital'}]}, { 'given': 'Mina Michael', 'family': 'Nesim', 'sequence': 'additional', 'affiliation': [{'name': 'Ain Shams University Hospital'}]}, { 'given': 'Mohamed Farouk', 'family': 'Allam', 'sequence': 'additional', 'affiliation': [{'name': 'Ain Shams University Hospital'}]}], 'member': '8761', 'reference': [ { 'key': 'ref1', 'unstructured': 'World Health Organization. Coronavirus disease (covid-19) - events as ' 'they happen.Available from: ' 'https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. ' 'Accessed on 2023 Apr 29.'}, { 'key': 'ref2', 'unstructured': 'Centres for Disease Control and Prevention. "Coronavirus disease 2019 ' '(COVID-19) 2021 case definition. Available from: ' 'https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/ ' 'Accessed on 2023 Apr 29.'}, { 'issue': '10', 'key': 'ref3', 'doi-asserted-by': 'publisher', 'first-page': '1564', 'DOI': '10.1017/S000711452000361X', 'article-title': 'Coronavirus disease 2019: think about the link', 'volume': '28', 'author': 'Angurana SK', 'unstructured': 'Angurana SK, Bansal A. Coronavirus disease 2019: think about the link. ' 'Br J Nutr. 2021 Nov;28(10):1564–70. 10.1017/S000711452000361X.', 'journal-title': 'Br J Nutr'}, { 'issue': '8', 'key': 'ref4', 'doi-asserted-by': 'publisher', 'first-page': '506', 'DOI': '10.1038/nrgastro.2014.66', 'article-title': 'Expert consensus document. The International Scientific Association for ' 'Probiotics and Prebiotics consensus statement on the scope and ' 'appropriate use of the term probiotic', 'volume': '11', 'author': 'Hill C', 'unstructured': 'Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, ' 'Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus ' 'document. The International Scientific Association for Probiotics and ' 'Prebiotics consensus statement on the scope and appropriate use of the ' 'term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506–14. ' '10.1038/nrgastro.2014.66.', 'journal-title': 'Nat Rev Gastroenterol Hepatol'}, { 'issue': '4', 'key': 'ref5', 'doi-asserted-by': 'publisher', 'first-page': '335', 'DOI': '10.1016/S2468-1253(20)30048-0', 'article-title': 'Enteric involvement of coronaviruses: Is faecal-oral transmission of ' 'SARS-CoV-2 possible? Lancet Gastroenterol Hepatol', 'volume': '5', 'author': 'Yeo C', 'unstructured': 'Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: Is ' 'faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol ' 'Hepatol. 2020 Apr;5(4):335–7. doi: 10.1016/S2468-1253(20)30048-0.'}, { 'issue': '8', 'key': 'ref6', 'doi-asserted-by': 'publisher', 'first-page': '1543', 'DOI': '10.1136/gutjnl-2020-321388', 'article-title': 'Faecal calprotectin indicates intestinal inflammation in COVID-19', 'volume': '69', 'author': 'Effenberger M', 'unstructured': 'Effenberger M, Grabherr F, Mayr L, Schwaerzler J, Nairz M, Seifert M, ' 'Hilbe R, Seiwald S, Scholl-Buergi S, Fritsche G, Bellmann-Weiler R, ' 'Weiss G, Müller T, Adolph TE, Tilg H. Faecal calprotectin indicates ' 'intestinal inflammation in COVID-19. Gut. 2020 Aug;69(8):1543–4. ' '10.1136/gutjnl-2020-321388.', 'journal-title': 'Gut'}, { 'key': 'ref7', 'doi-asserted-by': 'publisher', 'author': 'Zhang H', 'unstructured': 'Zhang H, Yeh C, Jin Z, Ding L, Liu BY, Zhang L, Dannelly HK. Prospective ' 'study of probiotic supplementation results in immune stimulation and ' 'improvement of upper respiratory infection rate. Synth Syst Biotechnol. ' '2018 Mar 12;3(2):113–120. doi: 10.1016/j.synbio.2018.03.001.', 'DOI': '10.1016/j.synbio.2018.03.001'}, { 'issue': '3', 'key': 'ref8', 'doi-asserted-by': 'publisher', 'first-page': '944', 'DOI': '10.1053/j.gastro.2020.05.048', 'article-title': 'Alterations in Gut Microbiota of Patients With COVID-19 During Time of ' 'Hospitalization', 'volume': '159', 'author': 'Zuo T', 'unstructured': 'Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, et al. Alterations in ' 'Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. ' 'Gastroenterology. 2020 Sep;159(3):944–955e8. ' '10.1053/j.gastro.2020.05.048.', 'journal-title': 'Gastroenterology'}, { 'issue': '1', 'key': 'ref9', 'doi-asserted-by': 'publisher', 'first-page': 'e001455', 'DOI': '10.1136/rmdopen-2020-001455', 'article-title': 'Beneficial effects of colchicine for moderate to severe COVID-19: a ' 'randomised, double-blinded, placebo-controlled clinical trial', 'volume': '7', 'author': 'Lopes MI', 'unstructured': 'Lopes MI, Bonjorno LP, Giannini MC, Amaral NB, Menezes PI, Dib SM, et ' 'al. Beneficial effects of colchicine for moderate to severe COVID-19: a ' 'randomised, double-blinded, placebo-controlled clinical trial. RMD Open. ' '2021 Feb;7(1):e001455. 10.1136/rmdopen-2020-001455.', 'journal-title': 'RMD Open'}, { 'issue': '3', 'key': 'ref10', 'doi-asserted-by': 'publisher', 'first-page': '341', 'DOI': '10.1016/j.semarthrit.2015.06.013', 'article-title': 'Colchicine-Update on mechanisms of action and therapeutic uses', 'volume': '45', 'author': 'Leung YY', 'unstructured': 'Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on mechanisms of ' 'action and therapeutic uses. Semin Arthritis Rheum. 2015 ' 'Dec;45(3):341–50. 10.1016/j.semarthrit.2015.06.013.', 'journal-title': 'Semin Arthritis Rheum'}, { 'issue': '8', 'key': 'ref11', 'doi-asserted-by': 'publisher', 'first-page': '924', 'DOI': '10.1016/S2213-2600(21)00222-8', 'article-title': 'Colchicine for community-treated patients with COVID-19 (COLCORONA): a ' 'phase 3, randomised, double-blinded, adaptive, placebo-controlled, ' 'multicentre trial', 'volume': '9', 'author': 'Tardif J-C', 'unstructured': "Tardif J-C, Bouabdallaoui N, L'Allier PL, Gaudet D, Shah B, Pillinger " 'MH, et al. Colchicine for community-treated patients with COVID-19 ' '(COLCORONA): a phase 3, randomised, double-blinded, adaptive, ' 'placebo-controlled, multicentre trial. Lancet Respir Med. 2021 ' 'Aug;9(8):924–32. 10.1016/S2213-2600(21)00222-8.', 'journal-title': 'Lancet Respir Med'}, { 'key': 'ref12', 'doi-asserted-by': 'publisher', 'first-page': 'm2980', 'DOI': '10.1136/bmj.m2980', 'article-title': 'Drug treatments for covid-19: living systematic review and network ' 'meta-analysis', 'volume': '30;370', 'author': 'Siemieniuk RAC', 'unstructured': 'Siemieniuk RAC, Bartoszko JJ, Zeraatkar D, Kum E, Qasim A, Díaz Martinez ' 'JP et al. Drug treatments for covid-19: living systematic review and ' 'network meta-analysis. BMJ 2020 Jul 30;370:m2980. doi: ' '10.1136/bmj.m2980.', 'journal-title': 'BMJ 2020 Jul'}, { 'issue': '6', 'key': 'ref13', 'doi-asserted-by': 'publisher', 'first-page': '643', 'DOI': '10.1080/00498254.2021', 'article-title': 'Colchicine for the treatment of COVID-19 patients: efficacy, safety, ' 'and model informed dosage regimens', 'volume': '51', 'author': 'Karatza E', 'unstructured': 'Karatza E, Ismailos G, Karalis V. Colchicine for the treatment of ' 'COVID-19 patients: efficacy, safety, and model informed dosage regimens. ' 'Xenobiotica. 2021 Jun;51(6):643–56. 10.1080/00498254.2021.', 'journal-title': 'Xenobiotica'}, { 'issue': '1', 'key': 'ref14', 'doi-asserted-by': 'publisher', 'first-page': 'e116', 'DOI': '10.7861/clinmed. Let.21.1.2', 'article-title': 'Discharge criteria for patients with COVID-19 to long-term care ' 'facilities requires modification', 'volume': '21', 'author': 'Teranaka W', 'unstructured': 'Teranaka W, Pan D. Discharge criteria for patients with COVID-19 to ' 'long-term care facilities requires modification. Clin Med (Lond). 2021 ' 'Jan;21(1):e116–7. 10.7861/clinmed. Let.21.1.2.', 'journal-title': 'Clin Med (Lond)'}, { 'key': 'ref15', 'doi-asserted-by': 'publisher', 'author': 'Doerre A', 'unstructured': 'Doerre A, Doblhammer G. The influence of gender on COVID-19 infections ' 'and mortality in Germany: Insights from age- and gender-specific ' 'modeling of contact rates, infections, and deaths in the early phase of ' 'the pandemic. PLoS One. 2022 May 6;17(5): e0268119. doi: ' '10.1371/journal.pone.0268119.', 'DOI': '10.1371/journal.pone.0268119'}, { 'issue': '1', 'key': 'ref16', 'doi-asserted-by': 'publisher', 'first-page': '9', 'DOI': '10.1186/s12954-020-00437-5', 'article-title': 'Smoking prevalence among hospitalized COVID-19 patients and its ' 'association with disease severity and mortality: an expanded ' 're-analysis of a recent publication', 'volume': '16', 'author': 'Farsalinos K', 'unstructured': 'Farsalinos K, Bagos PG, Giannouchos T, Niaura R, Barbouni A, Poulas K. ' 'Smoking prevalence among hospitalized COVID-19 patients and its ' 'association with disease severity and mortality: an expanded re-analysis ' 'of a recent publication. Harm Reduct J 2021 Jan 16;18(1):9. doi: ' '10.1186/s12954-020-00437-5.', 'journal-title': 'Harm Reduct J 2021 Jan'}, { 'issue': '11', 'key': 'ref17', 'doi-asserted-by': 'publisher', 'first-page': '1061', 'DOI': '10.1016/S2213-2600(22)00226-0', 'article-title': 'Onset and window of SARS-CoV-2 infectiousness and temporal correlation ' 'with symptom onset: a prospective, longitudinal, community cohort study', 'volume': '10', 'author': 'Hakki S', 'unstructured': 'Hakki S, Zhou J, Jonnerby J, Singanayagam A, Barnett JL, Madon KJ, et ' 'al. Onset and window of SARS-CoV-2 infectiousness and temporal ' 'correlation with symptom onset: a prospective, longitudinal, community ' 'cohort study. Lancet Respir Med. 2022 Nov;10(11):1061–73. ' '10.1016/S2213-2600(22)00226-0.', 'journal-title': 'Lancet Respir Med'}, { 'key': 'ref18', 'unstructured': 'Centres for Disease Control and Prevention. SARS-COV-2 variant ' 'classifications and definitions; Available from: ' 'https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html. ' 'Accessed on 2023 Apr 29.'}, { 'key': 'ref19', 'doi-asserted-by': 'publisher', 'first-page': '103593', 'DOI': '10.1016/j.amsu.2022.103593', 'article-title': 'Randomized controlled trial of colchicine add on to the standard ' 'therapy in moderate and severe corona virus Disease-19 infection', 'volume': '77', 'author': 'Gorial FI', 'unstructured': 'Gorial FI, Maulood MF, Abdulamir AS, Alnuaimi AS, abdulrrazaq MK, Bonyan ' 'FA. Randomized controlled trial of colchicine add on to the standard ' 'therapy in moderate and severe corona virus Disease-19 infection. Ann ' 'Med Surg (Lond). 2022 May;77:103593. 10.1016/j.amsu.2022.103593.', 'journal-title': 'Ann Med Surg (Lond)'}, { 'key': 'ref20', 'doi-asserted-by': 'publisher', 'author': 'Dorward J', 'unstructured': 'Dorward J, Yu L-M, Hayward G, Saville BR, Gbinigie O, Van Hecke O et al. ' 'Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, ' 'controlled, adaptive platform trial. Br J Gen Pract. 2022 Jun ' '30;72(720): e446-e455. doi: 10.3399/BJGP.2022.0083.', 'DOI': '10.3399/BJGP.2022.0083'}, { 'key': 'ref21', 'doi-asserted-by': 'crossref', 'unstructured': 'Colchicine in patients admitted to hospital with covid-19 (recovery): ' 'Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a ' 'randomised, controlled, open-label, platform trial. Lancet Respir Med. ' '2021 Dec;9(12):1419–1426. doi: 10.1016/S2213-2600(21)00435-5.', 'DOI': '10.1016/S2213-2600(21)00435-5'}, { 'issue': '6', 'key': 'ref22', 'doi-asserted-by': 'publisher', 'first-page': '823', 'DOI': '10.1111/1440-1681.13488', 'article-title': 'Colchicine treatment can improve outcomes of coronavirus disease 2019 ' '(COVID-19): A systematic review and meta-analysis', 'volume': '48', 'author': 'Hariyanto TI', 'unstructured': 'Hariyanto TI, Halim DA, Jodhinata C, Yanto TA, Kurniawan A. Colchicine ' 'treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A ' 'systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2021 ' 'Jun;48(6):823–30. 10.1111/1440-1681.13488.', 'journal-title': 'Clin Exp Pharmacol Physiol'}, { 'key': 'ref23', 'doi-asserted-by': 'publisher', 'author': 'AbdelFattah EB', 'unstructured': 'AbdelFattah EB, Korra EEA, Ahmed MA. Use of colchicine in COVID-19 ' 'hospitalized patients. Egypt J Chest Dis Tuberc 2022; 71:290-5. ' '2022;71(3):290. doi: 10.4103/ecdt.ecdt_59_21.', 'DOI': '10.4103/ecdt.ecdt_59_21'}, { 'issue': '4', 'key': 'ref24', 'doi-asserted-by': 'publisher', 'first-page': '1060', 'DOI': '10.1002/art.27327', 'article-title': 'High versus low dosing of oral colchicine for early acute gout flare: ' 'Twenty-four-hour outcome of the first multicenter, randomized, ' 'double-blind, placebo-controlled, parallel-group, dose-comparison ' 'colchicine study', 'volume': '62', 'author': 'Terkeltaub RA', 'unstructured': 'Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High ' 'versus low dosing of oral colchicine for early acute gout flare: ' 'Twenty-four-hour outcome of the first multicenter, randomized, ' 'double-blind, placebo-controlled, parallel-group, dose-comparison ' 'colchicine study. Arthritis Rheum 2010 Apr;62(4):1060–8. doi: ' '10.1002/art.27327.', 'journal-title': 'Arthritis Rheum 2010'}, { 'key': 'ref25', 'doi-asserted-by': 'publisher', 'author': 'Yasmin F', 'unstructured': 'Yasmin F, Najeeb H, Moeed A, Hassan W, Khatri M, Asghar MS et al. Safety ' 'and efficacy of colchicine in COVID-19 patients: A systematic review and ' 'meta-analysis of randomized control trials. PLoS One. 2022 Apr 5;17(4): ' 'e0266245. doi: 10.1371/journal.pone.0266245.', 'DOI': '10.1371/journal.pone.0266245'}, { 'key': 'ref26', 'doi-asserted-by': 'crossref', 'unstructured': 'Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., … Tian, D. S. ' 'Dysregulation of Immune Response in Patients with Coronavirus 2019 ' '(COVID-19) in Wuhan, China. Clin Infect Dis. 2020 Jul 28;71(15):762–768. ' 'doi: 10.1093/cid/ciaa248.', 'DOI': '10.1093/cid/ciaa248'}, { 'key': 'ref27', 'doi-asserted-by': 'publisher', 'author': 'Soraya GV', 'year': '2020', 'unstructured': 'Soraya GV, Ulhaq ZS. Crucial laboratory parameters in COVID-19 diagnosis ' 'and prognosis: An updated meta-analysis. Med Clin (Barc). 2020 Aug ' '28;155(4):143–151. doi: 10.1016/j.medcli.2020.05.017.', 'DOI': '10.1016/j.medcli.2020.05.017'}, { 'key': 'ref28', 'doi-asserted-by': 'publisher', 'author': 'Deftereos SG', 'unstructured': 'Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, ' 'Gargalianos P et al. Effect of Colchicine vs Standard Care on Cardiac ' 'and Inflammatory Biomarkers and Clinical Outcomes in Patients ' 'Hospitalized with Coronavirus Disease 2019: The GRECCO-19 Randomized ' 'Clinical Trial. JAMA Netw Open. 2020 Jun 1;3(6): e2013136. doi: ' '10.1001/jamanetworkopen.2020.13136.', 'DOI': '10.1001/jamanetworkopen.2020.13136'}, { 'issue': '12', 'key': 'ref29', 'doi-asserted-by': 'publisher', 'first-page': 'e24057', 'DOI': '10.1002/jcla.24057', 'article-title': 'COVID-19, and hematological parameters: A meta-analysis', 'volume': '35', 'author': 'Sarwar M', 'unstructured': 'Sarwar M, Ali Z, Fatima M, Sarfraz Z, Sarfraz A, Cherrez-Ojeda I, ' 'Colchicine. COVID-19, and hematological parameters: A meta-analysis. J ' 'Clin Lab Anal. 2021 Dec;35(12):e24057. 10.1002/jcla.24057. Epub 2021 Oct ' '28.', 'journal-title': 'J Clin Lab Anal'}, { 'key': 'ref30', 'doi-asserted-by': 'publisher', 'first-page': '8865954', 'DOI': '10.1155/2020/8865954', 'article-title': 'Case Control Study to Evaluate the Impact of Colchicine on Patients ' 'Admitted to the Hospital with Moderate to Severe COVID-19 Infection', 'volume': '27', 'author': 'Sandhu T', 'year': '2020', 'unstructured': 'Sandhu T, Tieng A, Chilimuri S, Franchin G. Case Control Study to ' 'Evaluate the Impact of Colchicine on Patients Admitted to the Hospital ' 'with Moderate to Severe COVID-19 Infection. Can J Infect Dis Med ' 'Microbiol 2020 Oct. 2020;27:8865954. 10.1155/2020/8865954.', 'journal-title': 'Can J Infect Dis Med Microbiol 2020 Oct'}, { 'key': 'ref31', 'doi-asserted-by': 'crossref', 'unstructured': 'Wischmeyer, P. E., Tang, H., Ren, Y., Bohannon, L., Ramirez, Z. E., ' 'Andermann, T.M., … Sung, A. D. (2022). Daily Lactobacillus probiotic ' 'versus placebo in COVID-19-exposed household contacts(PROTECT-EHC): a ' 'randomized clinical trial. MedRxiv, 2022-01. doi: ' 'https://doi.org/10.1101/2022.01.04.21268275.', 'DOI': '10.1101/2022.01.04.21268275'}, { 'key': 'ref32', 'doi-asserted-by': 'publisher', 'first-page': '91', 'DOI': '10.1016/j.ijid.2021.02.011', 'article-title': 'The effect of probiotics on respiratory tract infection with special ' 'emphasis on COVID-19: Systemic review 2010-20', 'volume': '105', 'author': 'Darbandi A', 'unstructured': 'Darbandi A, Asadi A, Ghanavati R, Afifirad R, Darb Emamie A, kakanj M et ' 'al. The effect of probiotics on respiratory tract infection with special ' 'emphasis on COVID-19: Systemic review 2010-20. Int J Infect Dis 2021 ' 'Apr; 105:91–104. doi: 10.1016/j.ijid.2021.02.011.', 'journal-title': 'Int J Infect Dis 2021'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://www.researchsquare.com/article/rs-3049708/v1', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.researchsquare.com/article/rs-3049708/v1.html', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 6, 13]], 'date-time': '2023-06-13T20:48:56Z', 'timestamp': 1686689336000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.researchsquare.com/article/rs-3049708/v1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 6, 13]]}, 'references-count': 32, 'URL': 'http://dx.doi.org/10.21203/rs.3.rs-3049708/v1', 'relation': {}, 'published': {'date-parts': [[2023, 6, 13]]}, 'subtype': 'preprint'}